TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - GALAPAGOS

TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - GALAPAGOS Stock

DE000SV2Y7G4

Delayed Deutsche Boerse AG 07:21:00 2024-05-31 EDT
1.79 ^EUR	-1.65%

Current month	+10.30%
1 month	+10.30%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart GALAPAGOS NV

Chart TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - GALAPAGOS

Latest news about GALAPAGOS NV

Galapagos, Adaptimmune to Jointly Develop Head, Neck Cancer Treatment	05:05am	MT
Galapagos, Adaptimmune Therapeutics Team Up to Evaluate Head and Neck Cancer Drug	04:04am	MT
Galapagos : Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T cell therapy candidate, uza cel, in head & neck cancer and potential future so	03:05am	PU
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications	05-30	GL

More news

Quotes 5-day view

Date	Price	Change
24-05-31	1.79	-1.65%
24-05-30	1.82	0.00%
24-05-29	1.82	+1.11%
24-05-28	1.8	+1.12%
24-05-27	1.78	-1.11%

Delayed Quote Deutsche Boerse AG

Last update May 31, 2024 at 07:21 am

More quotes

Static data

Product type	Knock-Out without Stop Loss
Buy / Sell	PUT
Underlying	GALAPAGOS NV
Issuer	Société Générale
WKN	SV2Y7G
ISIN	DE000SV2Y7G4
Date issued	2023-04-03
Strike	42.8 €
Maturity	Unlimited
Parity	10 : 1
Emission price	0.89 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	1.83 €
Lowest since issue	0.22 €
Spread	0.01 €
Spread %	0.56%

Company Profile

Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. The company is committed to improving patients' lives worldwide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.

Sector

More about the company

Ratings for Galapagos NV

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Galapagos NV

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

25.28 EUR

Average target price

36.73 EUR

Spread / Average Target

+45.29%

Consensus